Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04991922 · ClinicalTrials.gov registry record
BostonGene-Integrated Genomic Registry (BIGR)
A clinical trial of Malignancy, sponsored by BostonGene.
- Recruiting
- Registry status
- 100,000
- Enrollment target
- 1
- Study location
NCT04991922 is a study of Malignancy that is actively recruiting participants, run by BostonGene. The registered enrollment target is 100,000 participants, above the 87-participant average among 8 other Malignancy trials with a reported enrollment target (114843% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04991922, a study of Malignancy, is actively recruiting participants, sponsored by BostonGene.
- RECRUITING
- Registry status
- 100,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types
Conditions Studied
Study Locations (1)
Massachusetts
- BostonGene - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2036-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04991922
The ClinicalTrials.gov registry entry for NCT04991922 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 87-participant average among 8 other Malignancy trials with a reported enrollment target (114843% higher). The listed sponsor is BostonGene, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignancy appearing as the primary indexed condition, and to 0 interventions.
NCT04991922 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04991922 about?
NCT04991922 is a clinical study titled "BostonGene-Integrated Genomic Registry (BIGR)". The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types
What is the current status of trial NCT04991922?
This trial is currently recruiting. The enrollment target is 100,000 participants. The study started on 2021-07-01. Estimated completion is 2036-07-01.
What conditions does trial NCT04991922 study?
This clinical trial studies the following conditions: Malignancy.
Who is sponsoring clinical trial NCT04991922?
This trial is sponsored by BostonGene, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04991922 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
RECRUITING · NA
-
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
RECRUITING · Phase 1
-
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
RECRUITING
-
Immuno-Oncology Database and Bioregistry
ACTIVE NOT RECRUITING
-
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
ACTIVE NOT RECRUITING · Phase 2
-
Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.